The good times will go on for most health plans in terms of earnings through the rest of this year, experts believe.

That's because rate hikes are "in excess of medical trends," Rob Mains, an analyst with Advest, tells Business Insurance.

Greg Crawford, an analyst with Fox-Pitt Kelton, agrees. "Right now, it appears that premium rates will continue to track with medical costs," he says. "Medical costs are escalating, so you've got a situation where the companies are pricing in line with their expected cost, and I don't see any of the underlying economics of the industry disrupting that, so I think the outlook is stable and strong."

According to 2002 year-end results, the big winners are Health Net, Coventry, WellPoint, Anthem, UnitedHealth Group, and Humana.

There is a cloud on the horizon, however. HMOs are enjoying their earnings at employers' expense, and no one knows how long that can continue.

"Our goal is to try to get enough of a moderation in the health care cost trend to create an environment where the premiums aren't quite as high," David Olson, Health Net's vice president for investor relations, tells BI. "We're hearing from employers that they would like to find a way to lower premiums."

Evidence exists that employers aren't waiting for health plans to lead the way.

For instance, the Leapfrog Group focuses on improving patient safety as a way of reducing costs. Some employers want more monitoring of providers in order to pass that information on to employees. But that's not the only thing that will be passed on. Cost-shifting is being discussed more, but does not seem to have taken hold as much as Mains thinks it should have by now.

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.